Liver Cancer Open Access
Copyright ©2005 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 14, 2005; 11(2): 208-211
Published online Jan 14, 2005. doi: 10.3748/wjg.v11.i2.208
Prediction of HLA-A2-restricted CTL epitope specific to HCC by SYFPEITHI combined with polynomial method
Hai-Long Dong, Yan-Fang Sui, Department of pathology, Fourth Military Medical University, Xi’an 710032, Shaanxi Province, China
Author contributions: All authors contributed equally to the work.
Supported by Natural Scientific Foundation of China, No. 39830420
Correspondence to: Professor Yan-Fang Sui, Department of Pathology, Fourth Military Medical University, Xi’an 710032, Shaanxi Province, China. suiyanf@fmmu.edu.cn
Telephone: +86-29-3374541-211 Fax: +86-29-3374597
Received: November 4, 2003
Revised: November 8, 2003
Accepted: December 16, 2003
Published online: January 14, 2005

Abstract

AIM: To predict the HLA-A2-restricted CTL epitopes of tumor antigens associated with hepatocellular carcinoma (HCC).

METHODS: MAGE-1, MAGE-3, MAGE-8, P53 and AFP were selected as objective antigens in this study for the close association with HCC. The HLA-A*0201 restricted CTL epitopes of objective tumor antigens were predicted by SYFPEITHI prediction method combined with the polynomial quantitative motifs method. The threshold of polynomial scores was set to -24.

RESULTS: The SYFPEITHI prediction values of all possible nonamers of a given protein sequence were added together and the ten high-scoring peptides of each protein were chosen for further analysis in primary prediction. Thirty-five candidates of CTL epitopes (nonamers) derived from the primary prediction results were selected by analyzing with the polynomial method and compared with reported CTL epitopes.

CONCLUSION: The combination of SYFPEITHI prediction method and polynomial method can improve the prediction efficiency and accuracy. These nonamers may be useful in the design of therapeutic peptide vaccine for HCC and as immunotherapeutic strategies against HCC after identified by immunology experiment.

Key Words: Hepatocellular carcinoma, HLA-A*0201, Cytotoxic T Lymphocyte, Epitope



INTRODUCTION

Cancer immunotherapy has become one of the most important therapeutic procedures in the past two decades. Induction of potent anti-tumor cytotoxicity T lymphocytes (CTL) responses can result in regression and prevention of metastasis, as demonstrated in experimental model systems. Thus, efforts towards the development of cancer immunotherapy have recently focused on the generation of tumor-specific T cell responses. Over the last few years, several human genes that code for tumor antigens recognized by autologous CTL have been isolated[1-3] and the epitopes derived from these tumor antigens have been further identified to serve as targets for CTL in the context of HLA class I molecules[4].

Hepatocellular carcinoma (HCC) is one of the commonest malignant diseases in China and some other parts of Asia. Although encouraging advances have been made in the past few decades, there are still many difficulties in treating advanced-stage patients and in preventing recurrence and metastasis[5]. Immunotherapy is considered promising despite the fact that it is still a supplementary method in clinical practice[6,7]. The frequency of HLA-A2 allele in HCC patients is 53.5% in Chinese population[8]. It is very valuable to identify the tumor antigen epitopes which are presented by HLA-A2 and able to induce epitope-specific CTL against HCC cells.

In this study, we report a simple and efficient prediction method to identify candidate HLA-A2 restricted CTL epitopes from the tumor antigen that is closely associated with HCC.

MATERIALS AND METHODS
Materials

MAGE-1 (309aa), MAGE-3 (314aa), MAGE-8 (234aa), P53 (393aa) and AFP (609aa) were selected as objective antigens in this study for the close association with HCC. The amino acid sequences of these tumor antigens were quoted from EMBL database.

Methods

SYFPEITHI prediction Database retrieval can be performed on any HTML-browser supporting JavaScript. The main page of the database (http://www.uni-tuebingen.de/uni/kxi/) offers three sections: “Find Your Motif”, “Epitope prediction” and “Information”. After a preselection of one or multiple MHC-types, the “Epitope prediction” section allows the user to predict candidate epitope from protein sequence of a tumor antigen. The sequences of the protein or its gene, the restriction element are available.

The frequent of HLA-A2 types in HCC patients is 53.5% in the Chinese population and HLA-A*0201 is the major subtype of HLA-A2 allele, the HLA-A*0201 type was chosen from the frame of “Select MHC type”. In this study, the nonamers (9aa) were chosen from the frame of “Choose a nonamer” due to the typical length of a class I ligand comprised 9 amino acids (nonamers). Following the amino acid sequences of each tumor antigen were inputted, the epitope prediction program was processed immediately. The values of all possible nonamers of a given sequence were added together and the ten high-scoring peptides of each antigen were selected as optimal T-cell epitope for further study.

Polynomial method analysis

The basic premise of this method is independent binding of individual side-chains (IBS). When residue R occurs at position i in the peptide, it is assumed to contribute a constant amount Ri to the free energy of binding of the peptide irrespective of the sequence of the rest of the peptide. Parameters Ri are estimated from a training set of 161 peptides by a method analogous to that used by epidemiologists to calculate risk factors for developing a disease. All peptides in the training set contain the canonical motif for HLA-A2.1, so that they all contain the “correct” residue at the anchor positions (2 and 9). For i other than 2 and 9 (for the non-anchor positions), the average negative log10 of IC50 of all the peptides carrying R at position i is calculated and used as the estimate of Ri. This is a slightly modified version of the method reported by Ruppert et al[9]. The values of the Ri terms of HLA-A2 specificity are shown in Table 1.

Table 1 Coefficients for the polynomial method.
ResPosition
123456789
A-2.38-3.22-2.8-2.66-2.89-2.7-2.35-3.07-2.49
C-2.94-15-2.58-1.96-3.29-2.22-2.97-2.37-15.0
D-3.69-15-3.46-2.71-2.26-2.63-3.61-3.03-15.0
E-3.64-15-3.51-2.65-3.39-3.41-3.21-2.63-15.0
F-1.89-15-2.35-2.5-1.34-2.43-2.18-1.71-15.0
G-2.32-15-3.04-2.63-2.56-2.3-3.13-2.96-15.0
H-2.67-15-2.58-2.58-2.05-3.32-3.13-2.16-15.0
I-1.65-2.55-2.8-3.44-2.74-2.79-2.2-2.69-2.1
K-2.51-15-3.65-2.93-3.34-3.77-2.97-3.27-15
L-2.32-1.7-2.09-2.49-2.71-2.63-2.62-2.01-2.74
M-0.39-1.39-1.79-3.01-3.43-1.38-1.33-0.97-2.96
N-3.12-15-3.31-2.22-2.36-2.3-3.14-3.31-15.0
P-3.61-15-2.97-2.64-2.42-2.31-1.83-2.42-15.0
Q-2.76-15-2.81-2.63-3.06-2.84-2.12-3.05-15.0
R-1.92-15-3.41-2.61-3.05-3.76-3.43-3.02-15.0
S-2.39-15-2.04-2.12-2.83-3.04-2.73-2.02-15.0
T-2.89-3.58-2.6-2.48-2.17-2.58-2.67-3.14-3.7
V-2.44-2.64-2.68-3.29-2.49-2.25-2.68-2.8-1.7
W-0.14-15-1.01-2.94-1.77-2.77-2.85-2.13-15.0
Y-1.46-15-1.67-2.7-1.92-2.39-1.35-3.37-15.0

To calculate the polynomial method score of peptides in this study, the Ri values corresponding to the sequence of the given peptide were added together. If this sum exceeded a chosen threshold, the peptide was predicted to bind. The threshold was chosen as the number that gave a relatively clean separation between binders and non-binders in the training set. In the present study the threshold was -24.

Prediction result analysis

The previously reported CTL epitope of the antigens investigated in this study were obtained from the “Find Your Motif” section of SYFPEITHI database. These epitopes were screened out from the primary predicted epitopes.

RESULTS
SYFPEITHI prediction

The SYFPEITHI prediction values of all possible nonamers of a given protein sequence were added together and the ten high-scoring peptides of each protein were selected for further analysis. Scores for all predicted epitopes specifically for HLA-A*0201 are given in Table 2. The predicted epitopes were accorded with the simple motif (SM) of HLA-A2.1 (the presence of L, M or I at position 2 and L, V or I at position 9). The SYFPEITHI predicted scores of these epitopes were usually higher than 20.

Table 2 HLA-A2 restricted epitope prediction results.
AntigensAAposSequenceSYFPEITHI scorePolynomial score
MAGE-1 (MAG1)194F L I I V L V M I27-17.07
38L V L G T L E E V26-20.77
278K V L E Y V I K V26-21.23
101V I T K K V A D L25-24.23
301A L R E E E E G V25-24.81
187Q I M P K T G F L24-23.24
93I L E S L F R A V23-22.32
105K V A D L V G F L23-23.12
15A L E A Q Q E A L22-25.17
89S T S C I L E S L22-23.31
MAGE-3 (MAG3)108A L S R K V A E L31-22.04
201L L I I V L A I I28-22.52
200G L L I I V L A I27-22.33
271F L W G P R A L V27-19.47
220K I W E E L S V L26-23.01
112K V A E L V H F L25-23.14
237S I L G D P K K L25-22.73
176Y I F A T C L G L23-21.73
238I L G D P K K L L23-23.01
174H L Y I F A T C L22-21.3
MAGE-8 (MAG8)111A L D E K V A E L33-23.5
45L I M G T L E E V29-21.63
204L L I I V L G M I26-21.58
115K V A E L V R F L24-23.44
179Y I L V T C L G L24-22.1
71S L T V T D S T L23-23.39
203G L L I I V L G M23-23.08
205L I I V L G M I L23-22.73
20G E A P G L M D V21-34.01
25L M D V Q I P T A21-23.75
P53 (P53)24K L L P E N N V L26-23.31
187G L A P P Q H L I25-21.96
264L L G R N S F E V24-21.58
129A L N K M F C Q L23-24.94
132K M F C Q L A K T22-23.22
193H L I R V E G N L22-24.86
65R M P E A A P P V21-20.47
322P L D G E Y F T L21-25.24
256T L E D S S G N L20-25.86
113F L H S G T A K S19-34.05
AFP (FETA)90Q L P A F L E E L27-22.64
257K L V L D V A H V27-20.1
158F M N K F I Y E I26-20.37
172F L Y A P T I L L25-19.87
410A L A K R S C G L25-24.57
218L L N Q H A C A V24-22.45
242K L S Q K F T K V24-22.29
571V I A D F S G L L23-22.76
599L I S K T R A A L23-23.93
8F L I F L L N F T22-22.78
Polynomial method analysis

The primary predicted epitopes were compared with epitopes that were demonstrated in previous research. Six reported HLA-A2 restricted CTL epitopes (MAGE-1278-286KVLEYVIKV[10], MAGE-3112-120KVAELVHFL[11], MAGE-3271-279 FLWGPRALV[12], P53187-197GLAPPQHLIRV[13], P53322-330 PLDGEYFTL[14], AFP158-166 FMNKFIYEI[15]) were eliminated from the SYFPEITHI prediction results. The polynomial scores of predicted epitopes are shown in Table 2. The epitopes which polynomial scores less than -24 (MAGE-1101-109, 301-309, 15-23, MAGE-820-28, P53129-137, 193-201, 256-264, 113-121, AFP410-418) were eliminated from the prediction results. At last, thirty-five epitopes were selected from the predicted results for further study.

DISCUSSION

The induction of antigen-specific cytotoxic T lymphocytes (CTL) has been suggested to be efficacious in the prevention and treatment of various types of tumor. Determination of peptides that elicit a T-cell response in vivo is important for identifying autoimmune and CTL epitopes and for peptide vaccine design. About 120 CTL epitopes presented by HLA-A, B, C molecules have been reported in recent study[4] and some epitopes have been used as peptide vaccine in animal and clinical experiments[16,17].

While sufficient conditions for a peptide to be a T-cell epitope are not well known, one well established necessary condition is that they bind to MHC molecules. Hence considerable effort has been made to measure the binding affinities of peptides to MHC molecules. A reliable theoretical method that rapidly predict whether a peptide bind is of great practical utility. The methods of epitope prediction were constructed by immunologists in recent decades. These predictions are based on comparisons of precursor peptide sequences known to contain T cell epitopes. It is the discovery of allele-specific motifs shared by eluted natural MHC ligands that finally allow the exact prediction of peptides from a given protein sequence presented on MHC class I molecules. Currently, several algorithms are publicly available for predicting the HLA-binding affinities of peptides, such as the SYFPEITHI database (http://uni-tuebingen.de/uni/kxi/)[18]. SYFPEITHI uses motif matrices deduced from refined motifs based on the pool sequence and single peptide analysis exclusively of natural ligands. Potential binders for various MHC class I molecules are ranked according in the presence of primary and secondary anchor amino acids as well as favored and disfavored amino acids.

However, motifs are the simplest independent binding site models: they specify positions with required residues and certain other positions with prohibited residues. One way to include more detail than motifs in an independent binding model is the polynomial method. Polynomial method is based on statistical parameter estimation assuming independent binding of the side-chains of residues[9]. Its sensitivity and positive predictive value are better than the simple motif (such as syfpeithi database)[19]. This and other[20-22] independent binding site methods that assign a score to a peptide have been called quantitative motifs[23]. Threshold is an integral part of the polynomial method. In the above analysis the threshold was set to -24. In this study, 35 candidate epitopes were selected for further immunology experiments by the SYFPEITHI prediction combined with polynomial methods.

Hepatocellular carcinoma (HCC) is one of the most common neoplasms worldwide. It is the major cause of death in China and some regions of Asia. The pathogenic mechanisms responsible for HCC are not well defined, and therapeutic means, especially in unresectable HCCs, are still unsatisfactory. In Chinese HCC patients, the proportion of HLA-A2 is higher than other alleles[8]. Therefore, identification of HLA-A2 restricted CTL epitopes of tumor antigen closely associated with HCC is very valuable for HCC immunotherapy in China. In this study, the antigens of MAGE gene family(MAGE-1, MAGE-3 and MAGE-8), P53 mutation gene and AFP were selected as objective proteins because these antigens have been demonstrated to be closely associated with HCC[24-26,15]. The candidate HLA-A2 restricted CTL epitopes of these antigens were predicted using the syfpeithi prediction combined with polynomial methods.

The epitope prediction has been carried in tumor antigen specificity for CTL epitope identification in most studies recently. Schirle et al[14] reported that two new CTL epitopes of gastrointestinal tumor were identified by epitope prediction combined with acid eluted methods. Epitope prediction also has been combined with epitope reconstruction and immunology assay by Pascolo et al[10] and a new CTL epitope of MAGE-1 was identified.

If immunological activity of the candidate epitopes has been identified by further immunology assay, most of the patients with HCC could be potentially candidates for specific immunotherapy against these epitopes, including vaccination using APC pulsed with HLA-A2-restricted CTL epitopes or the adoptive transfer of specific CTL generated from PBMC by stimulation with the epitopes. The results of this study will benefit to most patients with HCC in the future.

Footnotes

Edited by Wang XL and Xu FM

References
1.  Dong HL, Sui YF, Li ZS, Qu P, Wu W, Ye J, Zhang XM, Lu SY. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro. Cancer Lett. 2004;211:219-225.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 4]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
2.  van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-1647.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2388]  [Cited by in F6Publishing: 2299]  [Article Influence: 69.7]  [Reference Citation Analysis (0)]
3.  Katsura F, Eura M, Chikamatsu K, Oiso M, Yumoto E, Ishikawa T. Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24. Jpn J Clin Oncol. 2000;30:117-121.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 6]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
4.  Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 2001;50:3-15.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 295]  [Cited by in F6Publishing: 300]  [Article Influence: 13.0]  [Reference Citation Analysis (0)]
5.  Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, El-Kamary SS, Bass EB. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology. 2002;36:S84-S92.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 54]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
6.  Butterfield LH, Ribas A. Immunotherapy of hepatocellular carcinoma. Expert Opin Biol Ther. 2002;2:123-133.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 18]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
7.  Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, Strong R, Leggett B, Powell L, Maddern G. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol. 2002;17:889-896.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 51]  [Cited by in F6Publishing: 54]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
8.  Ming LH, Zhu YR, Harris CC, Wang XH, Wu ZY, Sun ZT. Association of HLA-A02 genotype with hepatocellular carcinoma in a prevalent area of China. Chin J Immunol. 1999;15:305-310.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell. 1993;74:929-937.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 468]  [Cited by in F6Publishing: 510]  [Article Influence: 16.5]  [Reference Citation Analysis (0)]
10.  Pascolo S, Schirle M, Gückel B, Dumrese T, Stumm S, Kayser S, Moris A, Wallwiener D, Rammensee HG, Stevanovic S. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res. 2001;61:4072-4077.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998;59:1-14.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 164]  [Cited by in F6Publishing: 152]  [Article Influence: 5.8]  [Reference Citation Analysis (0)]
12.  van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994;24:3038-3043.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 256]  [Cited by in F6Publishing: 270]  [Article Influence: 9.0]  [Reference Citation Analysis (0)]
13.  Theobald M, Biggs J, Hernández J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med. 1997;185:833-841.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 197]  [Cited by in F6Publishing: 201]  [Article Influence: 7.4]  [Reference Citation Analysis (0)]
14.  Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanović S, Rammensee HG. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol. 2000;30:2216-2225.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 3]  [Reference Citation Analysis (0)]
15.  Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH, Economou JS. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol. 2001;166:5300-5308.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 106]  [Cited by in F6Publishing: 106]  [Article Influence: 4.6]  [Reference Citation Analysis (0)]
16.  Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669-1678.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 928]  [Cited by in F6Publishing: 942]  [Article Influence: 37.7]  [Reference Citation Analysis (0)]
17.  Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol. 2002;38:158-164.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 113]  [Cited by in F6Publishing: 118]  [Article Influence: 5.4]  [Reference Citation Analysis (0)]
18.  Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213-219.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1764]  [Cited by in F6Publishing: 1722]  [Article Influence: 68.9]  [Reference Citation Analysis (0)]
19.  Gulukota K, Sidney J, Sette A, DeLisi C. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol. 1997;267:1258-1267.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 200]  [Cited by in F6Publishing: 209]  [Article Influence: 7.7]  [Reference Citation Analysis (0)]
20.  Marshall KW, Wilson KJ, Liang J, Woods A, Zaller D, Rothbard JB. Prediction of peptide affinity to HLA DRB1*0401. J Immunol. 1995;154:5927-5933.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152:163-175.  [PubMed]  [DOI]  [Cited in This Article: ]
22.  Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med. 1994;180:2353-2358.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 215]  [Cited by in F6Publishing: 203]  [Article Influence: 6.8]  [Reference Citation Analysis (0)]
23.  Hammer J. New methods to predict MHC-binding sequences within protein antigens. Curr Opin Immunol. 1995;7:263-269.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 38]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
24.  Tahara K, Mori M, Sadanaga N, Sakamoto Y, Kitano S, Makuuchi M. Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer. 1999;85:1234-1240.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 4]  [Reference Citation Analysis (0)]
25.  Kobayashi Y, Higashi T, Nouso K, Nakatsukasa H, Ishizaki M, Kaneyoshi T, Toshikuni N, Kariyama K, Nakayama E, Tsuji T. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J Hepatol. 2000;32:612-617.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 46]  [Cited by in F6Publishing: 48]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
26.  Charuruks N, Tangkijvanich P, Voravud N, Chatsantikul R, Theamboonlers A, Poovorawan Y. Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients. J Gastroenterol. 2001;36:830-836.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 19]  [Cited by in F6Publishing: 21]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]